Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
16.7M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
1.04K
-
Shares change
-
0
-
Total reported value, excl. options
-
$2.43K
-
Price
-
$2.33
Significant Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q4 2023
1 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.04K shares
of 16.7M outstanding shares and own 0.01% of the company stock.
Largest 10 shareholders include EVENTIDE ASSET MANAGEMENT, LLC (1.39M shares), Cormorant Asset Management, LP (1.39M shares), CITADEL ADVISORS LLC (1.18M shares), Soleus Capital Management, L.P. (704K shares), Parkman Healthcare Partners LLC (696K shares), DSC Advisors, L.P. (696K shares), AlphaCentric Advisors LLC (668K shares), Palo Alto Investors LP (445K shares), PRELUDE CAPITAL MANAGEMENT, LLC (118K shares), and Exome Asset Management LLC (118K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.